Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: What PTSC must do.

currently the retailshareholders are at risk of havingtheir portion of the PDS cash distributions diluted each time

PTSC offers new stock and or options or warrants to employees/consultants/directors.  Additionally I believe any M&A will inlcude much greater dilution to the tune of 25-30%  ( a 50 million purchase at the current share price would require 100mmi shares of stock)

PTSC has no way to proect the cash from teh 35% corp tax rate.

Therefore the cash is taxed at 35% and then if distrubuted in dividends we aretaxed at

15% So 100 recieved by PTSC is 65 and then if 50% is distributed then we recieve 32.50 pay 15% tax and are left with a bout 28$ land PTSC keeps 32.50. A total of 60.50

 If instead PTSC would keep the whole 100 then  they would have 65 dollars

If we used the pass through then PTSC would receive 50 and keep 

the same 32.50  but the shareholders would recieve 50 as a partnership distribution and pay 28% tax and keep 36 dollars or more if these distributions can be offset against other partnership losses that the shareholder is carryng. This totals to 68.50 

 

More importantly current shareholders do not suffer the continual dilution that I project will total some 30% over the next two years relative to our entitlement to licensing fees  

 

 

 

Share
New Message
Please login to post a reply